Search Results - "Gasal, E."

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes by Platzbecker, U, Symeonidis, A, Oliva, E N, Goede, J S, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J

“…The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had…”
Get full text

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM) by Weber, J., Long, G.V., Haanen, J.B., Arance, A., Dummer, R., Nathan, P., Ribas, A., Ascierto, P.A., Robert, C., Gasal, E., D’Amelio, A., Bettinger, S., Boran, A.D., Schadendorf, D.

Get full text

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS) by Platzbecker, U, Symeonidis, A, Oliva, E, Goede, J, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J

Get full text

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma by Robert, Caroline, Grob, Jean J, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Gogas, Helen, Mandalá, Mario, Haanen, John B.A.G, Lebbé, Celeste, Mackiewicz, Andrzej, Rutkowski, Piotr, Nathan, Paul D, Ribas, Antoni, Davies, Michael A, Flaherty, Keith T, Burgess, Paul, Tan, Monique, Gasal, Eduard, Voi, Maurizio, Schadendorf, Dirk, Long, Georgina V

“…In long-term follow-up of more than 500 patients with melanoma containing a BRAF V600E or V600K mutation, a combination of dabrafenib plus trametinib was…”
Get full text

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma by Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M, Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V, Schadendorf, Dirk

“…At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III…”
Get full text

1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors by Calvo, E., Joerger, M., Läubli, H., Lopez, J.S., Alonso, G., Corral de la Fuente, E., Hess, D., König, D., Perez, V., Gasal, E., Jethwa, S., Di Blasi, D., Garralda, E.

Get full text

1337P - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials by Robert, C., Schadendorf, D., Dummer, R., Flaherty, K.T., Tawbi, H.A., Menzies, A.M., D’Amelio, A., de Jong, E., Gasal, E., Long, G.V.

“…D+T has been approved for several indications, including BRAF V600–mutant unresectable or metastatic melanoma and as adjuvant therapy following resected BRAF…”
Get full text

1337PAnalysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials by Robert, C, Schadendorf, D, Dummer, R, Flaherty, K T, Tawbi, H A, Menzies, A M, D’Amelio, A, de Jong, E, Gasal, E, Long, G V

“…Abstract Background D+T has been approved for several indications, including BRAF V600–mutant unresectable or metastatic melanoma and as adjuvant therapy…”
Get full text

Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials by Robert, C., Schadendorf, D., Dummer, R., Flaherty, K.T., Tawbi, H.A., Menzies, A.M., D’Amelio, A., de Jong, E., Gasal, E., Long, G.V.

Get full text

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial by Nathan, P., Dummer, R., Long, G.V., Ascierto, P.A., Tawbi, H.A., Robert, C., Rutkowski, P., Leonov, O., Dutriaux, C., Mandala', M., Lorigan, P., Ferrucci, P.F., Flaherty, K.T., Brase, J.C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., Schadendorf, D.

Get full text

561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours by LoRusso, P., Fakih, M., De Vos, F.Y.F.L., Beck, J.T., Merchan, J., Shapiro, G., Lin, C-C., Desai, J., Spratlin, J., Cascella, T., Sandalic, L., Abdelhady, A.M., Boran, A., Gasal, E., Janku, F., Van Cutsem, E.

Get full text

1333P - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting by Grob, J.J., Atkinson, V.G., Robert, C., Schadendorf, D., Nathan, P., Davies, M.A., Kefford, R., Dummer, R., Kirkwood, J.M., Flaherty, K.T., Ribas, A., Burgess, P., Gasal, E., Long, G.V., Hauschild, A.

“…In a pooled analysis of COMBI-d (NCT01584648) and COMBI-v (NCT01597908) trials, D+T led to long-term disease control in many pts and 5-y survival in…”
Get full text

1333PAdverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting by Grob, J J, Atkinson, V G, Robert, C, Schadendorf, D, Nathan, P, Davies, M A, Kefford, R, Dummer, R, Kirkwood, J M, Flaherty, K T, Ribas, A, Burgess, P, Gasal, E, Long, G V, Hauschild, A

“…Abstract Background In a pooled analysis of COMBI-d (NCT01584648) and COMBI-v (NCT01597908) trials, D+T led to long-term disease control in many pts and 5-y…”
Get full text

Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting by Grob, J.J., Atkinson, V.G., Robert, C., Schadendorf, D., Nathan, P., Davies, M.A., Kefford, R., Dummer, R., Kirkwood, J.M., Flaherty, K.T., Ribas, A., Burgess, P., Gasal, E., Long, G.V., Hauschild, A.

Get full text

1304TiPA randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM) by Weber, J, Long, G V, Haanen, J B, Arance, A, Dummer, R, Nathan, P, Ribas, A, Ascierto, P A, Robert, C, Gasal, E, D'Amelio, A, Bettinger, S, Boran, A D, Schadendorf, D

Get full text

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial by Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek

“…Effective treatments are needed to improve outcomes for high-grade glioma and low-grade glioma. The activity and safety of dabrafenib plus trametinib were…”
Get full text

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma by Dummer, Reinhard, Arance Fernández, Ana María, Hansson, Johan, Larkin, James M. G., Long, Georgina V., Gasal, Eduard, Kaper, Mathilde, Upalawanna, Allison, Mookerjee, Bijoyesh, Atkinson, Victoria

“…Abstract only 189 Background: Checkpoint inhibitors and targeted therapies have improved outcomes in pts with advanced BRAF V600–mutant melanoma; however, many…”
Get full text

42 - A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS) by Platzbecker, U., Symeonidis, A., Oliva, E., Goede, J., Delforge, M., Mayer, J., Slama, B., Badre, S., Gasal, E., Mehta, B., Franklin, J.

Get full text

A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i) by Gasal, E, Fernandez, AMA, Ascierto, PA, Atkinson, V, Dummer, R, Flaherty, KT, Grob, JJ, Hansson, J, Hassel, J, Larkin, J, Lebbe, C, Long, GV, Lorigan, P, Miller, W, Nathan, P, Ribas, A, Robert, C, Schadendorf, D, Tawbi, H, Upalawanna, A

Get full text

Listeria species escape from the phagosomes of interleukin-4-deactivated human macrophages independent of listeriolysin by Neumann, Katja, Eppler, Elisabeth, Filgueira, Luis, Groscurth, Peter, Gasal, Eduard, Schaffner, Andreas, Schoedon, Gabriele, Schneemann, Markus

“…Listeria monocytogenes is the causative agent of infections like sepsis and meningitis, especially in immunocompromised hosts. Human macrophages are able to…”
Get full text